… surgery in anaplastic thyroid carcinoma (ATC), particularly with the advent of neoadjuvant-targeted
therapeutics. The … We highlight considerable variability in the approach to surgical re- …

… This review article aims to provide a summary of the current therapeutic strategies in
advanced RAIR-DTC, including approved target therapies as well as those for off-label use, RAI …

… recurrence allow an accurate evaluation of the tumor recurrence risk for each patient [4,5].
Progressively, a more personalized therapeutic approach has been developed according to …

… with dabrafenib/trametinib were FDA approved for BRAF-mutated anaplastic thyroid cancer
(ATC), after they showed remarkable improvement in overall survival in these patients in a …

… follicular, and oncocytic thyroid carcinoma; (2) medullary thyroid cancer, which is sometimes
… (3) anaplastic thyroid cancer, which often arises from differentiated thyroid cancer and has a …

… Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy of the thyroid
gland, … The keywords for this abstract include: anaplastic thyroid carcinoma, thyroid cancer, …

… The recent advances in understanding the molecular … of thyroid cancer have led to a better
therapeutic approach of … differentiated thyroid cancer (DTC), anaplastic thyroid carcinoma …

… approach that should be tested in clinical trials [1,18]. Nevertheless, in Europe the approved
therapeutic options for advanced … ATC patients targeted therapies and checkpoint inhibitors. …

… refractoriness, and tumors can progress, albeit rarely (1–6%), … [3] and undifferentiated
anaplastic thyroid carcinoma (ATC) [4… perspective of the molecular pathogenesis of thyroid cancer. …

… multi-step iterative approach; … cancer, none have been approved for thyroid cancer. There
are, however, case reports of the successful use of ALK inhibitors in anaplastic thyroid cancer (…